Microgynon® ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,342 /  Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04086225 (ClinicalTrials.gov)	January 17, 2019	9/9/2019	Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany	NULL	Recruiting	18 Years	45 Years	Female	34	Phase 1	Germany;Poland
2	NCT03745144 (ClinicalTrials.gov)	January 17, 2019	14/11/2018	Effects of Cladribine Tablets on the PK of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMS	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck KGaA, Darmstadt, Germany	NULL	Active, not recruiting	18 Years	45 Years	Female	24	Phase 1	Germany;Poland